The 9 analysts offering 12-month price forecasts for Reata Pharmaceuticals Inc have a median target of 67.00, with a high estimate of 75.00 and a low estimate of 35.00. The median estimate represents a +149.35% increase from the last price of 26.87.
The current consensus among 9 polled investment analysts is to Buy stock in Reata Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.10
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.